Compare Goldman Sachs Group Inc (GS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Goldman Sachs (GS) trades at $893.95, down 0.15% with bearish technical signals but strong fundamental performance. The stock shows consistent earnings beats with Q3 2026 EPS of $17.01 exceeding expectations by 32%. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 29.46%. Recent news highlights the company's focus on expanding its $70B revenue base and AI initiatives.

GS presents a compelling value case with a P/E of 13.77 below industry averages, supported by 40% analyst buy ratings and a $1,130 consensus price target. However, negative operating cash flow trends and bearish technical indicators suggest near-term volatility. The dividend yield of approximately 0.56% provides income support while the company executes its growth strategy.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.